{"id":7249,"date":"2015-10-22T14:02:05","date_gmt":"2015-10-22T14:02:05","guid":{"rendered":"\/?p=7249"},"modified":"2015-10-22T14:14:54","modified_gmt":"2015-10-22T14:14:54","slug":"positiveid-corp-otcmktspsid-compensates-for-monday-slip","status":"publish","type":"post","link":"\/articles\/positiveid-corp-otcmktspsid-compensates-for-monday-slip\/","title":{"rendered":"PositiveID Corp (OTCMKTS:PSID) Compensates for Monday Slip"},"content":{"rendered":"\n

Following a red session on Monday that sent the share price of PositiveID Corp (OTCMKTS:PSID<\/a>) below its 200-day moving average, the stock bounced back yesterday and made up for the slip. By the closing bell PSID<\/a> was sitting at $0.024 per share, on volume of 7.9 million shares traded.<\/p>\n

PSID<\/a> has been keeping a relatively low profile on the press release front. The company last put up an official announcement on Oct 12, informing investors that development of the Firefly Dx prototype – the company’s flagship product – has hit a major milestone. The Firefly Dx is a detection and diagnosis tool for point-of-need use that uses polymerase reaction to detect pathogens.<\/p>\n

The new Firefly now has real-time optics implemented in its design, which in turn enables monitoring fluorescence measurements. In layman’s terms, this helps first responders with identifying and understanding the quality of the test and the amount of pathogen in the sample in the testing unit.<\/p>\n

The company’s latest available quarterly report for Q2 contains the following:<\/p>\n